In­no­va­tive coat­ing makes hos­pi­tals bet­ter,healthier

China Daily (Hong Kong) - - SWEDEN SPECIAL -

Bac­ti­guard started in 2005 with one mis­sion: to re­duce hos­pi­tal- ac­quired in­fec­tions trans­mit­ted through med­i­cal de­vices.

Its in­no­va­tive tech­nol­ogy is based on the Swedish in­dus­tri­al­ist Gustaf Dalén’s No­bel Prize-win­ning re­search from 1912, on au­to­matic reg­u­la­tors for use in con­junc­tion with gas ac­cu­mu­la­tors to il­lu­mi­nate light­houses and buoys.

Chris­tian Kinch, founder and CEO of Bac­ti­guard, founded the com­pany af­ter meet­ing the in­ven­tor Billy Söder­vall.

Söder­vall had de­vel­oped Dalén’s re­search and pro­duced a unique metal al­loy that can be per­ma­nently bonded to the sur­face of any med­i­cal ac­ces­sory — lim­it­ing bac­te­rial ad­he­sion and pre­vent­ing its re­pro­duc­tion.

He is 70 years old this year, and is still very ac­tive in Bac­ti­guard.

“Bac­ti­guard’s prod­ucts can re­duce HAI by up to 73 per­cent, ac­cord­ing to our lat­est study,” says Kinch.

“Since 1995, over 125 mil­lion pa­tients have used catheters coated with Bac­ti­guard’s patented tech­nol­ogy around the world.”

HAI is cur­rently the fourth largest cause of death in the Western world, be­hind only car­dio­vas­cu­lar disease, can­cer and strokes.

Bac­ti­guard’s tech­nol­ogy aims to re­duce this sig­nif­i­cantly, sav­ing lives and health­care ex­penses. “If our fo­ley catheters were used in only 50 per­cent of China’s hos­pi­tals, it could pre­vent up to 200,000 uri­nary tract in­fec­tions and more than 5,000 re­lated deaths each year, while also sav­ing the Chi­nese health­care sys­tem over $650 mil­lion in costs as­so­ci­ated with HAI treat­ment,” he said.

Cur­rently, over 60 per­cent of HAI around the world is caused by the use of uri­nary tract catheters, cen­tral ve­nous catheters and en­do­tra­cheal tubes. Bac­ti­guard has all of th­ese three ar­eas cov­ered in its in­fec­tion pro­tec­tion prod­uct port­fo­lio. The po­ten­tial for its tech­nol­ogy is nearly lim­it­less, since the al­loy is in­vis­i­ble and per­ma­nent: with ap­pli­ca­tions pos­si­ble on any­thing from door han­dles to con­tact lenses. It is also bio­com­pat­i­ble, mean­ing it is tis­sue-friendly.

“My job’s real re­ward is know­ing that ev­ery day we save some­one’s life by pro­tect­ing him or her from HAI,” says Kinch. “This pushes us to ex­pand our mar­ket share to help even more pa­tients. Know­ing that we are help­ing so many in­di­vid­u­als is what gets me out of bed ev­ery morn­ing.”

The use of Bac­ti­guard’s in­fec­tion-pre­vent­ing prod­ucts has had another pos­i­tive side ef­fect: the greatly re­duced need for an­tibi­otics.

Mod­ern so­ci­ety’s overuse of an­tibi­otics is lead­ing to mul­tire­sis­tant bac­te­ria that are in­creas­ingly im­mune to many types of treat­ment.

In fact, the World Health Or­ga­ni­za­tion de­scribes mi­cro­bial re­sis­tance as one of the great­est threats to hu­man health to­day.

Al­ready present in 30 coun­tries around the world, Bac­ti­guard is now in­tro­duc­ing its prod­ucts to the Chi­nese mar­ket. Part­ner­ing with the phar­ma­ceu­ti­cal dis­trib­u­tor, Jian An, it aims to tap this huge mar­ket through its part­ner’s sales net­work — with the goal of mak­ing its prod­ucts even­tual main­stays in Chi­nese hos­pi­tals.

Kinch un­der­stands that China is cru­cial to Bac­ti­guard’s ex­pan­sion plans, and hopes that bring­ing Bac­ti­guard’s prod­ucts to a wide sec­tion of the Chi­nese pub­lic will ben­e­fit even more peo­ple than it has al­ready helped so far.

www.bac­ti­ World Eye Re­ports pro­vided the story

Newspapers in English

Newspapers from China

© PressReader. All rights reserved.